Decellularization of human donor aortic and pulmonary valved conduits using low concentration sodium dodecyl sulfate

• DOI: 10.1002/term.2391
• Publication Date: 2016-12-12T06:58:45Z
• Authors: Tayyebeh Vafaee; Daniel Thomas; Amisha Desai; Louise M. Jennings; Helen Berry; Paul Rooney; John Kearney; John Fisher; Eileen Ingham
• Keywords: Decellularization

The clinical use of decellularized cardiac valve allografts is increasing. Long-term data will be required to determine whether they outperform conventional cryopreserved allografts. Valves using different processes may show varied long-term outcomes. It therefore important understand the effects specific decellularization technologies on characteristics donor heart valves. Human aortic and pulmonary valved conduits were hypotonic buffer, 0.1% (w/v) sodium dodecyl sulfate nuclease digestion. tissues compared cellular histology, immunohistochemistry, quantitation total deoxyribose nucleic acid, collagen glycosaminoglycan content, in vitro cytotoxicity assays, uniaxial tensile testing subcutaneous implantation mice. showed no histological evidence cells or cell remnants >97% acid removal all regions (arterial wall, muscle, leaflet junction). retained IV von Willebrand factor staining with some loss fibronectin, laminin chondroitin staining. There was an absence major histocompatibility complex Class I tissues, only residual isolated areas tissues. content not decreased following however reduced. Only moderate changes maximum load failure recorded postdecellularization. noncytotoxic vitro, biocompatible vivo a mouse implant model. process now translated into good manufacturing practices-compatible for valves view future use. Copyright © 2016 Authors Tissue Engineering Regenerative Medicine published by John Wiley & Sons, Ltd.